2024 年第 1 期 第 19 卷

来那度胺致多发性骨髓瘤继发第二原发肿瘤急性B淋巴细胞白血病1例报道并文献复习

Lenalidomide induced multiple myeloma secondary to second primary tumor acute B-lymphoblastic leukemia: a case report and literature review

作者：何晓玉1 马薇1 荣爱红2 田文灏1 闫洪超2 王冲1 邢彩霞1 刘爱琪1 尹亚南1 石凤芹1

英文作者：He Xiaoyu1 Ma Wei1 Rong Aihong2 Tian Wenhao1 Yan Hongchao2 Wang Chong1 Xing Caixia1 Liu Aiqi1 Yin Yanan1 Shi Fengqin1

单位：1北京中医药大学东直门医院血液肿瘤科，北京100700；2北京中医药大学东直门医院检验科，北京100700

英文单位：1Department of Hematologic Oncology Dongzhimen Hospital Beijing University of Chinese Medicine Beijing 100700 China; 2Department of Clinical Laboratory Dongzhimen Hospital Beijing University of Chinese Medicine Beijing 100700 China

关键词：多发性骨髓瘤；来那度胺；第二原发肿瘤；急性B淋巴细胞白血病

英文关键词：Multiplemyeloma;Lenalidomide;Secondprimarytumor;AcuteB-lymphoblasticleukemia

• 摘要：

• 多发性骨髓瘤（MM）是浆细胞肿瘤的一种类型，是以恶性浆细胞在骨髓克隆性增殖为特征的疾病，导致贫血和相关的血细胞减少、低丙种球蛋白血症、溶骨性骨病、高钙血症和肾功能不全。近年来新药的广泛应用，延长了MM患者的生存期，提高了随访率，但使远期并发症相对增多，其中第二原发肿瘤已经成为新的临床难题。本文报道1例来那度胺致MM继发第二原发肿瘤急性B淋巴细胞白血病患者，停止服用来那度胺4个月后完全缓解，并进行相关文献复习。

• Multiple myeloma (MM) is a type of plasma cell tumor characterized by clonal proliferation of malignant plasma cells in the bone marrow, resulting in anemia and associated cytopenia, hypogammaglobulinemia, osteolytic bone disease, hypercalcemia and renal insufficiency. In recent years, the wide application of new drugs prolongs the survival of MM patients and increases the follow-up rate, but the long-term complications are relatively increased, among which the second primary tumor has become a new clinical problem. This paper reports a patient with lenalidomide induced MM secondary to second primary tumor acute B-lymphoblastic leukemia, which has a complete remission at 4 months after discontinuation of lenalidomide, and reviews associated literatures.